Day One Biopharmaceuticals (Day One Biopharmaceuticals) YoY EPS Growth : -22.03% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Day One Biopharmaceuticals YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Day One Biopharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 was -22.03%.

Day One Biopharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.72.

Day One Biopharmaceuticals YoY EPS Growth Historical Data

The historical data trend for Day One Biopharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Day One Biopharmaceuticals YoY EPS Growth Chart

Day One Biopharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

-220.27

-379.25

53.03

-9.22

Day One Biopharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EPS Growth	Get a 7-Day Free Trial													-22.92	-1.67	-1.89	-14.29	-22.03

Day One Biopharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Day One Biopharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(-2.37	-	-2.17)	/	\| -2.17 \|
=	-9.22 %

Day One Biopharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EPS Growth (Q: Mar. 2024 )
=	(Earnings per Share (Diluted) (Q: Mar. 2024 )	-	Earnings per Share (Diluted) (Q: Mar. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Mar. 2023 )) \|
=	(-0.72	-	-0.59)	/	\| -0.59 \|
=	-22.03 %

Day One Biopharmaceuticals YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Day One Biopharmaceuticals's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Day One Biopharmaceuticals (Day One Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Day One Biopharmaceuticals Inc (NAS:DAWN) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

2000 Sierra Point Parkway, Suite 501, Brisbane, CA, USA, 94005

Website

https://www.dayonebio.com

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The lead product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Executives

York Charles N Ii	officer: COO, CFO and Secretary	901 S. MOPAC EXPRESSWAY, BARTON OAKS PLAZA ONE, SUITE 250, AUSTIN TX 78746
Samuel C. Blackman	officer: Chief Medical Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Jeremy Bender	director, officer: Chief Executive Officer	395 OYSTER POINT BLVD., SUITE 217, SOUTH SAN FRANCISCO CA 94080
Ai Day 1 Llc	10 percent owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Julie Papanek Grant	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Canaan Xi L.p.	10 percent owner	2765 SAND HILL RD, MENLO PARK CA 94025
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Atlas Venture Opportunity Fund Ii, L.p.	10 percent owner	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Michael Gladstone	director	395 OYSTER POINT BLVD, SUITE 217, SOUTH SAN FRANCISCO CA 94080
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Takeda Pharmaceuticals U.s.a., Inc.	10 percent owner	ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Takeda Ventures, Inc.	10 percent owner	9625 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
John A. Josey	director	C/O PELOTON THERAPEUTICS, INC., 2330 INWOOD ROAD, SUITE 226, DALLAS TX 75235